Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date
Hims & Hers launched injectable and oral testosterone replacement therapy options, its largest men's health expansion since introducing the category last September. The new lineup includes two injectables (a twice-weekly compounded option and once-weekly generic testosterone cypionate) plus Kyzatrex, an FDA-approved oral TRT shown to help up to 96% of men reach normal testosterone levels within 90 days. The expansion targets an estimated 20 million U.S.
Key figures
- Survey size
- 2000
- Kyzatrex efficacy
- up to 96% of men reach normal testosterone levels in 90 days
- Treatment awareness
- 45% familiar with specific low T treatments
- Addressable population
- 20 million U.S. men affected by low testosterone (cited estimate)
- Survey energy priority
- 79%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.